Table 3

Change in Outcome Measures after 8 weeks (Intention-to-treat analysis) (n = 55-60)

Variable

Blend 1

(mean ± SD)

Blend 2

(mean ± SD)

Placebo

(mean ± SD)


Endothelial Function

Flow-mediated dilatation, %

0.70 ± 3.70

0.70 ± 3.80

0.60 ± 3.70

Stimulus-adjusted response measure

-0.02 ± 0.23

-0.02 ± 0.21

-0.03 ± 0.21

Flow-mediated dilatation, % (acute effects)

1.1 ± 3.70

0.7 ± 3.5

-0.3 ± 5.4

Serum Measures

Insulin, pmol/L

68.06 ± 311.83

18.06 ± 213.21

15.97 ± 202.79

Fasting plasma glucose, mmol/L

0.03 ± 1.44

0.16 ± 1.47

0.38 ± 1.58

Anthropometric Measures

Body Weight, kg

0.40 ± 2.20

0.30 ± 2.80

0.40 ± 2.20

Body Mass Index, kg/m2

0.10 ± 0.80

0.10 ± 1.00

0.10 ± 0.80

Lipid Panel

Total Cholesterol, mmol/L

0.08 ± 0.47

0.08 ± 0.60

0.03 ± 0.52

High Density Lipoprotein (HDL), mmol/L

0.04 ± 0.17

0.04 ± 0.12

0.06 ± 0.15

Total Cholesterol/HDL

-0.10 ± 0.60

-0.10 ± 0.80

-0.30 ± 0.70

Triglycerides, mmol/L

0.02 ± 0.64

-0.01 ± 0.71

-0.13 ± 0.68

Low Density Lipoprotein (LDL), mmol/L

-0.02 ± 0.53

0.08 ± 0.62

0.02 ± 0.53


p > 0.05 for all pairwise comparisons

Ali et al. Nutrition Journal 2011 10:72   doi:10.1186/1475-2891-10-72

Open Data